Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.
Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.
MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.
MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive annual licensing fees, clinical development milestones, and royalties on net sales of the licensed products. This marks MaxCyte’s 28th clinical/commercial partnership, emphasizing its role in advancing cell-based therapeutics.
The partnership aims to enhance Legend Biotech’s non-viral engineered therapeutic pipeline, leveraging MaxCyte’s expertise in scalable cell engineering and regulatory support. The ExPERT™ platform provides high transfection efficiency and seamless scalability, essential for developing innovative cell therapies. Both companies aim to transform the treatment landscape and meet expanding clinical and commercial needs.
MaxCyte, Inc. reported a total revenue of $11.3 million in the first quarter of 2024, marking a 32% increase year-over-year. Core business revenue grew by 5% to $8.2 million. The company signed four Strategic Platform License (SPL) clients year-to-date, with a total of 27 partners. Cash, cash equivalents, and investments stood at $202.5 million as of March 31, 2024. MaxCyte affirmed its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $5 million in SPL Program-related revenue.
Summary not available.
Summary not available.
Summary not available.
Summary not available.